Whereas most glucose-lowering agents did not reduce the incidence of HF in T2DM patients in randomized control trials10, and SGLT2 inhibitors can reduce HF incidence, leading to fewer MACE and cardiovascular death in patients with T2DM11–13. The gene discussed is SLC5A2; the disease is hydrops fetalis.